American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL

ASH 2018 – CLL

Using a national claims database, researchers found that previously untreated patients receiving chemoimmunotherapy had a higher total cost of care compared with patients receiving single-agent ibrutinib. Read More ›

Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study

ASH 2018 – CLL

This phase 3 follow-up analysis evaluates the efficacy and safety of ibrutinib, alone and in combination with rituximab, in patients with Waldenström’s macroglobulinemia. Read More ›

Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

ASH 2018 – CLL

In an ex vivo analysis, the combination of venetoclax and ibrutinib showed encouraging biologic activity in several leukemia subtypes, including acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Read More ›

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL

ASH 2018 – CLL

In a phase 2 trial, the combination of ibrutinib and venetoclax was effective in patients with previously untreated, high-risk chronic lymphocytic leukemia (CLL), with no unforeseen safety signals. Read More ›

MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab

ASH 2018, ASH 2018 – CLL

Researchers evaluated venetoclax plus rituximab versus bendamustine plus rituximab in inducing deep, durable responses in patients with chronic lymphocytic leukemia, as measured by the rate of minimal residual disease. Read More ›

Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL

ASH 2018 – CLL

The combination of ibrutinib with obinutuzumab represents an effective chemotherapy-free treatment option for first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities. Read More ›

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

ASH 2018, ASH 2018 – CLL

The Bruton’s tyrosine kinase inhibitor acalabrutinib shows promise as a tolerable, effective monotherapy option for patients with previously untreated chronic lymphocytic leukemia. Read More ›

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL

ASH 2018 – CLL

In evaluating the combination regimen of obinutuzumab, ibrutinib, and venetoclax as a potential limited-duration option in chronic lymphocytic leukemia (CLL), researchers reported a high mid-therapy response rate of relapsed/refractory patients with promising rates of minimal residual disease–negativity. Read More ›

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL

ASH 2018, ASH 2018 – CLL

The ALLIANCE study showed that ibrutinib produces superior progression-free survival to standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL). Read More ›

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV

ASH 2018, ASH 2018 – CLL

The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL). Read More ›

American Society of Hematology (ASH)

Page 22 of 44